MeSH term
Frequency | Condition_Probility | Humans | 80 | 0.0 |
3T3 Cells | 3 | 0.0 |
Animals | 33 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Farnesol/*analogs & derivatives/*pharmacology | 2 | 100.0 |
Male | 35 | 0.0 |
Mice | 21 | 0.0 |
Mitogen-Activated Protein Kinases/drug effects/metabolism | 2 | 4.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 38 | 0.0 |
Salicylic Acids/*pharmacology | 6 | 85.0 |
Time Factors | 6 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Mice, Nude | 3 | 0.0 |
Rats | 11 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
ras Proteins/*antagonists & inhibitors | 4 | 66.0 |
English Abstract | 6 | 0.0 |
Immunity, Cellular | 3 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Thymic Factor, Circulating/*metabolism | 5 | 83.0 |
Cell Division | 3 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Kinetics | 5 | 0.0 |
Adolescent | 14 | 0.0 |
Child | 12 | 0.0 |
Child, Preschool | 13 | 0.0 |
Female | 33 | 0.0 |
Infant | 9 | 0.0 |
Rosette Formation | 9 | 2.0 |
Spleen/immunology | 2 | 1.0 |
Thymectomy | 2 | 6.0 |
Zinc/blood | 2 | 10.0 |
Research Support, U.S. Gov't, P.H.S. | 11 | 0.0 |
Swine | 2 | 0.0 |
Adult | 24 | 0.0 |
Aged | 13 | 0.0 |
Middle Aged | 13 | 0.0 |
Alkyl and Aryl Transferases/*antagonists & inhibitors | 2 | 5.0 |
Antineoplastic Agents/pharmacology/*therapeutic use | 2 | 5.0 |
Enzyme Inhibitors/pharmacology/*therapeutic use | 2 | 12.0 |
Farnesol/*analogs & derivatives/pharmacology | 7 | 100.0 |
Salicylic Acids/pharmacology | 4 | 33.0 |
Thymic Factor, Circulating/*physiology | 2 | 100.0 |
Mice, SCID | 2 | 0.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 2 | 2.0 |
Transplantation, Heterologous | 2 | 0.0 |
Cell Line | 9 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Syndrome | 4 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Binding Sites | 4 | 0.0 |
Rabbits | 2 | 0.0 |
Pregnancy | 3 | 0.0 |
Smoking | 2 | 0.0 |
Cattle | 3 | 0.0 |
Comparative Study | 10 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Lymphocyte Activation | 5 | 0.0 |
Thymic Factor, Circulating/*analysis | 6 | 85.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Reference Values | 2 | 0.0 |
T-Lymphocytes/immunology | 4 | 0.0 |
Thymic Factor, Circulating/analysis | 4 | 100.0 |
Thymus Gland/*physiopathology | 2 | 66.0 |
Radioimmunoassay | 2 | 0.0 |
Thymus Hormones/*pharmacology | 6 | 54.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Thymus Gland/*analysis | 2 | 66.0 |
Thymus Hormones/*analysis | 5 | 71.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Age Factors | 4 | 0.0 |
*Bone Marrow Transplantation | 3 | 0.0 |
Leukocyte Count | 4 | 0.0 |
Thymus Hormones/*physiology | 2 | 66.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Thymus Hormones/*secretion | 2 | 100.0 |
Glucose Tolerance Test | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Antigens, Surface/analysis | 4 | 0.0 |
Hybridomas/immunology | 2 | 1.0 |
Thymus Hormones/*immunology | 6 | 100.0 |
Thymic Factor, Circulating/*therapeutic use | 2 | 100.0 |
Thymus Hormones/*therapeutic use | 3 | 60.0 |
Thymus Hormones/*metabolism | 4 | 80.0 |
Leukemia, Lymphocytic/*metabolism | 2 | 50.0 |
Thymopentin | 2 | 33.0 |
Antibody Specificity | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Thymic Factor, Circulating/*pharmacology | 3 | 75.0 |
Concanavalin A/pharmacology | 3 | 1.0 |
Thymic Factor, Circulating/pharmacology | 2 | 100.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Thymic Factor, Circulating/*immunology | 4 | 100.0 |
Immunosorbent Techniques | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Aging | 2 | 0.0 |
